Pembrolizumab in performance status 2 patients with non-small cell lung cancer (NSCLC): Results of the PePS2 trial
- Resource Type
- Source
- ResearcherID
- Subject
0301 basic medicine Oncology medicine.medical_specialty Performance status Karnofsky Performance Status business.industry non-small cell lung cancer (NSCLC) Hematology Pembrolizumab medicine.disease 03 medical and health sciences 030104 developmental biology 0302 clinical medicine 030220 oncology & carcinogenesis Internal medicine medicine business - Language
- ISSN
- 0923-7534